Aldeyra Therapeutics (ALDX)
(Delayed Data from NSDQ)
$3.77 USD
-0.17 (-4.31%)
Updated May 10, 2024 04:00 PM ET
After-Market: $3.76 -0.01 (-0.27%) 7:58 PM ET
2-Buy of 5 2
D Value C Growth F Momentum F VGM
Price, Consensus and EPS Surprise
ALDX 3.77 -0.17(-4.31%)
Will ALDX be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for ALDX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ALDX
Is Aldeyra Therapeutics (ALDX) Outperforming Other Medical Stocks This Year?
Aldeyra (ALDX) Stock Rallies 43% in One Week: Here's Why
ALDX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Are Medical Stocks Lagging Aclaris Therapeutics (ACRS) This Year?
Here's Why You Should Invest in Aldeyra (ALDX) Stock Now
Is Aclaris Therapeutics (ACRS) Outperforming Other Medical Stocks This Year?
Other News for ALDX
Aldeyra enrolls first patient in dry eye chamber clinical trial
Aldeyra Therapeutics Enrolls First Patient in Phase 3 Clinical Trial Designed to Enable Potential Resubmission of New Drug Application of Reproxalap in Dry Eye Disease
Oppenheimer Keeps Their Buy Rating on Aldeyra Therapeutics (ALDX)
Analysts Offer Insights on Healthcare Companies: Owens & Minor (OMI), Vertex Pharmaceuticals (VRTX) and Aldeyra Therapeutics (ALDX)
ALDX Stock Earnings: Aldeyra Therapeutics Meets EPS for Q1 2024